Phase 2 Ovarian Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been newly diagnosed with stage III epithelial ovarian cancer (including cancer of the peritoneum or fallopian tubes), based on the FIGO classification system.
- People who have had upfront surgery where most of the tumour was removed, leaving behind less than 1 cm of remaining tumour.
- People who are able to begin follow-up cancer treatment within 6 weeks of their debulking surgery.
- People whose tumour has been tested using an FDA-approved test and found to have a feature called Homologous Recombination Proficiency (HRP) (confirm with trial site for details on this test).
- People who have a good general level of physical functioning, rated 0 or 1 on a standard medical scale called the ECOG scale, meaning they are fully active or have only minor limitations in physical activity.
- People whose liver, kidneys, and other organs are working well enough to meet the trial's health requirements.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have had a serious allergic reaction or other medical reason to avoid a substance called rhuGM-CSF.
- People who have had another cancer diagnosed within the last 5 years, with the exception of certain treated skin cancers or surface-level cancers that show no signs of returning.
- People who are currently taking medications that suppress the immune system, or who have taken such medications within the 4 weeks before starting the trial drugs.
- People who have an active or past autoimmune or inflammatory condition (where the immune system attacks the body).
- People who have an active infectious disease such as tuberculosis, hepatitis B, hepatitis C, or HIV.
- People who are pregnant, breastfeeding, or planning to become pregnant during the period covered by the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hyunwon Shin, MD, PhD, hyunwon.shin@astonsci.com
Phone: +82-2-2038-2347
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
Primary endpoints
Progression-Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.